0
settings
الوضع الليلي
moon
انماط الصفحة الرئيسية arrow
EN
1
المرجع الالكتروني للمعلوماتية

النبات

مواضيع عامة في علم النبات

الجذور - السيقان - الأوراق

النباتات الوعائية واللاوعائية

البذور (مغطاة البذور - عاريات البذور)

الطحالب

النباتات الطبية

الحيوان

مواضيع عامة في علم الحيوان

علم التشريح

التنوع الإحيائي

البايلوجيا الخلوية

الأحياء المجهرية

البكتيريا

الفطريات

الطفيليات

الفايروسات

علم الأمراض

الاورام

الامراض الوراثية

الامراض المناعية

الامراض المدارية

اضطرابات الدورة الدموية

مواضيع عامة في علم الامراض

الحشرات

التقانة الإحيائية

مواضيع عامة في التقانة الإحيائية

التقنية الحيوية المكروبية

التقنية الحيوية والميكروبات

الفعاليات الحيوية

وراثة الاحياء المجهرية

تصنيف الاحياء المجهرية

الاحياء المجهرية في الطبيعة

أيض الاجهاد

التقنية الحيوية والبيئة

التقنية الحيوية والطب

التقنية الحيوية والزراعة

التقنية الحيوية والصناعة

التقنية الحيوية والطاقة

البحار والطحالب الصغيرة

عزل البروتين

هندسة الجينات

التقنية الحياتية النانوية

مفاهيم التقنية الحيوية النانوية

التراكيب النانوية والمجاهر المستخدمة في رؤيتها

تصنيع وتخليق المواد النانوية

تطبيقات التقنية النانوية والحيوية النانوية

الرقائق والمتحسسات الحيوية

المصفوفات المجهرية وحاسوب الدنا

اللقاحات

البيئة والتلوث

علم الأجنة

اعضاء التكاثر وتشكل الاعراس

الاخصاب

التشطر

العصيبة وتشكل الجسيدات

تشكل اللواحق الجنينية

تكون المعيدة وظهور الطبقات الجنينية

مقدمة لعلم الاجنة

الأحياء الجزيئي

مواضيع عامة في الاحياء الجزيئي

علم وظائف الأعضاء

الغدد

مواضيع عامة في الغدد

الغدد الصم و هرموناتها

الجسم تحت السريري

الغدة النخامية

الغدة الكظرية

الغدة التناسلية

الغدة الدرقية والجار الدرقية

الغدة البنكرياسية

الغدة الصنوبرية

مواضيع عامة في علم وظائف الاعضاء

الخلية الحيوانية

الجهاز العصبي

أعضاء الحس

الجهاز العضلي

السوائل الجسمية

الجهاز الدوري والليمف

الجهاز التنفسي

الجهاز الهضمي

الجهاز البولي

المضادات الميكروبية

مواضيع عامة في المضادات الميكروبية

مضادات البكتيريا

مضادات الفطريات

مضادات الطفيليات

مضادات الفايروسات

علم الخلية

الوراثة

الأحياء العامة

المناعة

التحليلات المرضية

الكيمياء الحيوية

مواضيع متنوعة أخرى

الانزيمات

قم بتسجيل الدخول اولاً لكي يتسنى لك الاعجاب والتعليق.

Evasion of Immune Responses by Tumors

المؤلف:  Abbas, A. K., Lichtman, A. H., Pillai, S., & Henrickson, S. E.

المصدر:  Cellular and Molecular Immunology (2026)

الجزء والصفحة:  11E, P425-428

2026-11-14

240

+

-

20

 Evasion of host immunity is now considered a hallmark of cancer, meaning that in order to grow, tumors have to evade or resist host immune responses. Several mechanisms of immune evasion by tumors have been hypothesized and supported by experimental evidence or by clinical success of therapeutic approaches that target evasion mechanisms (Fig. 1). A major focus of tumor immunology is to understand these immune evasion mechanisms, with the goal that interventions to prevent immune evasion will increase the immunogenicity of tumors and maximize the effectiveness of the host response. Most evasion mechanisms can be categorized as either active inhibition of antitumor immune responses or loss of antigens that drive these responses.

Fig1. Mechanisms by which tumors escape immune defenses. Antitumor immunity develops when T cells recognize tumor antigens and are activated. Tumor cells may evade immune responses by losing the expression of antigens or major histocompatibility complex (MHC) molecules, and by producing ligands for T-cell inhibitory receptors and immunosuppressive cytokines. The tumor micromovement, which includes immunosuppressive myeloid cells and lymphocytes, inhibits the activation, differentiation, and infiltration of antitumor effector T cells. CTL, Cytotoxic T lymphocyte; MDSC, myeloid-derived supressor cell; PD-1, programmed cell death protein-1; PD-L1, PD ligand 1; TGF-β, transforming growth factor-β; Treg, regulatory T cell.

Loss of Tumor Antigen Expression

Immune responses to tumor cells impart selective pressures that result in the survival and outgrowth of variant tumor cells with reduced immunogenicity. Experiments comparing tumors that develop in normal mice versus Rag-deficient mice that lack adaptive immunity show that only in the setting of a normal immune system do tumors become less immunogenic over time, which is consistent with selective survival of less immunogenic clones. This phenomenon has been called immune editing, implying that the immune response selects for changes in tumors that help them evade the response. Given the high mitotic rate of tumor cells and their genetic instability, mutations or deletions in genes encoding tumor antigens are com mon. If these antigens are not required for growth of the tumors or maintenance of the transformed phenotype, the antigen negative tumor cells will have a growth advantage in the face of the host immune response. Recent studies have confirmed this occurs in cancer patients. Tumor-specific antigens that drive T-cell responses in the patients were identified by full exome sequencing and identification of mutant peptides that bound to the patients’ MHC alleles. In those patients, tumor subclones could be detected that no longer carried the mutations that encode immunogenic neoantigens.

MHC-I expression is often downregulated on tumor cells so they cannot present any tumor antigens to CD8+ T cells. This is likely a more effective form of immune evasion than mutational loss of individual antigens. Various tumors show decreased syn thesis of MHC-I molecules, or proteins required for MHC-I expression on the cell surface such as β2-microglobulin, or components of the antigen-processing machinery such as trans porter associated with antigen processing-1 (TAP1) and TAP2 and subunits of the proteasome. Loss of the expression of MHC-I molecules or of proteins involved in MHC assembly and anti gen presentation are due to mutations in the genes encoding these molecules. Tumor cells with such mutations presumably have a selective survival advantage because they can evade CTL mediated immune responses. As we discussed earlier, tumors that lose MHC-I are more likely to be recognized by NK cells. However, additional mutations that impair tumor cell expression of ligands for NK cell-activating receptors may emerge, promoting the outgrowth of subclones that also evade NK cell attack.

Molecules and Cells That Inhibit Immune Responses to Tumors

Tumors evade antitumor T-cell responses by engaging T-cell inhibitory (immune checkpoint) molecules that normally function to prevent autoimmunity or regulate immune responses to microbes. This has been shown most clearly for CTLA-4 (cytotoxic T lymphocyte–associated protein 4) and PD-1 (programmed cell death protein-1), two of the best-defined inhibitory receptors of T cells. The importance of these molecules in tumor immune evasion became clear from experimental work in mice showing that blockade of these inhibitors enhanced antitumor immunity, followed by successful clinical trials and now widely adopted use of anti-PD-1 and anti-CTLA-4 antibodies to treat cancers. Tumors are able to resist T-cell immune attack by upregulating the expression of PD-1 and CTLA-4 on tumor-specific T cells, probably as a result of chronic T-cell stimulation by persistent tumor antigens. Tumor-infiltrating T cells often have a dysfunctional (exhausted) phenotype that was first described in the context of chronic viral infections. Cancer and chronic viral infection are both associated with chronic antigen exposure and inflammation. Exhausted T cells are characterized by impaired effector functions and increased expression of CTLA-4, PD-1, and other inhibitory molecules. In addition to upregulating CTLA-4 on tumor-specific effector T cells, the TME may also promote differentiation of regulatory T cells, which express CTLA-4.

For PD-1 and CTLA-4 to function as T-cell inhibitors, they must bind their ligands. The ligands for PD-1 are the B7 family proteins PD-L1 (PD ligand 1) and PD-L2. Many tumors express PD-L1, sometimes because of PDL1 gene amplification, and some tumors express PD-L2. IFN-γ produced by tumor-infiltrating T cells also induces PD-L1 expression on tumor cells and on myeloid cells in the tumor microenvironment. Thus, many tumors or cells surrounding tumors can engage PD-1 on infiltrating T cells and stop the T cells from per forming their tumor-killing functions. The ligands for CTLA-4 are B7-1 and B7-2, which are costimulatory molecules mainly expressed on APCs in secondary lymphoid organs that work by engaging CD28. CTLA-4 binds B7 more strongly than CD28 does and removes B7 molecules from APCs, thus acting as a competitive inhibitor of T-cell costimulation (see Chapter 10). A possible reason why tumors can exploit CTLA-4 to regulate antitumor responses is that tumor antigens are often presented by APCs in the absence of strong innate immunity and hence with low levels of B7 costimulators on the APCs. These low levels may be preferentially bound up by the high-affinity receptor CTLA-4 on effector T cells and Tregs and therefore not accessible to CD28. In addition to PD-1 and CTLA-4, other inhibitory receptors expressed by tumor-specific T cells, including LAG3, TIM3, and TIGIT, may also contribute to the inhibition of anti tumor immune responses.

Secreted products of tumor cells may suppress antitumor immune responses. An example of an immunosuppressive tumor product is TGF-β, which is secreted by many tumors and inhibits the proliferation and effector functions of lymphocytes and macrophages.

Tregs may suppress T-cell responses to tumors. Evidence from mouse tumor studies and patients with cancer indicates that Tregs can be found in the cellular infiltrates in certain tumors. Depletion of Tregs in tumor-bearing mice enhances antitumor immunity and reduces tumor growth, and the presence of Tregs within human tumors correlates with prognosis.

Myeloid-derived suppressor cells (MDSCs) are immature myeloid precursors that accumulate in the bone marrow, lymphoid tissues, blood, and tumors of tumor-bearing animals and cancer patients and suppress innate and T cell–mediated anti tumor immune responses. MDSCs are a heterogeneous collection of different myeloid cell types, including cells that are most similar to monocytes, neutrophils, or DCs. In addition to patients with tumors, MDSCs also accumulate in tissues of patients with chronic inflammatory diseases. MDSCs are reported to suppress innate and adaptive immune responses by many different mechanisms, including secretion of immunosuppressive cytokines, such as IL-10 and TGF-β; production of arginase-1 (Arg-1), which depletes arginine that is needed for optimal T cell activation, and nitric oxide which inhibits T cell functions by several mechanisms; promotion of Treg differentiation; and inhibition of CTL and Th1 differentiation. Cyclooxygenase-2-dependent production of prostaglandin E2 may enhance the differentiation of MDSCs with these immunosuppressive functions. Although the presence of MDSCs in tumors correlates with impaired anti tumor immune responses, there are many gaps in our knowledge about the nature of these cells, how they develop and function, and how they can be targeted for therapeutic purposes. M2 macrophages activated by tumors may also inhibit antitumor immunity and promote tumor growth.

Immunosuppressive Features of the Tumor Microenvironment

Earlier in the chapter, we introduced the concept that cells in the TME may mediate antitumor responses, but the TME may be altered over time such that effective antitumor responses are impaired. This is a common phenomenon seen in many solid tumors. When the TME contains inflammatory cells that pro mote effective anti-tumor immune responses, the tumors are often referred to as being “hot”, but if the TME is devoid of stimulatory cells and the responses are suppressed, the tumor is described as “cold”. Within the TME are a diverse array of cells in addition to the cancer cells, including lymphocytes, dendritic cells, macrophages, neutrophils, MDSCs, vasculature cells, and fibroblasts. Through cell-cell interactions, and secretion of growth factors and cytokines, they contribute to shaping innate and adaptive immune responses to the cancer cells and to the formation of an extracellular tumor matrix and tumor vasculature. The TME is also often characterized by harsh metabolic conditions, including low levels of glucose, high acidity, and hypoxia. As tumors evolve, these various components and conditions of the TME often work to thwart the effectiveness of antitumor immunity by several mechanisms (Fig. 2).

• The TME favors differentiation of M2-like tumor-associated macrophages. Monocyte recruitment into tumors is driven by the chemokine CCL2 and in the TME they are prone to polarize to an M2 phenotype. The tumor-associated macrophages secrete the cytokines IL-10 and transforming growth factor-β (TGF-β), which inhibit the activity of antitumor Th1 cells and CTLs; TGF-β also supports Treg differentiation.

• M2 macrophages also secrete matrix metalloproteinases, enzymes that modify the extracellular tissue, allowing the cancer cells to invade tissues.

 • The TME skews the adaptive immune system toward responses that enhance rather than prevent tumor development. DCs in tumors drive CD4+ T-cell differentiation toward Th2 cells and regulatory T cells, both of which sup press Th1 and CTL responses that destroy tumors. Th2 cells secrete IL-4 and IL-13, which further increase the development of M2-like tumor-associated macrophages that pro mote tumor growth.

• The TME also promotes the development of MDSCs, which produce high levels of nitric oxide, arginine (Arg-1), and IL-10, which can inhibit the responses of effector T cells that enter the tumor.

• Vascular endothelial growth factor (VEGF), made by M2 macrophages, promotes the growth of blood vessels that supply the cancer cells with nutrients, and the vasculature supports tumor infiltration by myeloid-derived suppressor cells, but for incompletely understood reasons, the recruitment of CTLs and Th1 cells is impaired.

Fig2. Promotion of tumor growth by the antiinflammatory tumor microenvironment. Although inflammation can promote malignant transformation of cells and the development of cancers, established tumors often create a microenvironment that suppresses inflammation and antitumor immunity, which further promotes cancer cell growth. Tumors alter the phenotype of dendritic cells in ways that promote the differentiation of antiinflammatory regulatory T cells and Th2 cells, which in turn promote differentiation and accumulation of M2 macrophages and myeloid-derived suppressor cells. These cells block the action of anti tumor cytotoxic T lymphocytes (CTLs) and Th1 cells and provide growth factors for tumor cells and tumor blood vessels. (The blue arrows show changes or movement of cells, the black arrows show effects of released factors from tumors on immune cells or vice versa, and the red arrow refers to inhibition.)

Taken together, in the TME, the suppression of immune effector cells and the recruitment and activation of immunosuppressive cells are conducive to the immune escape of tumor cells leading to tumor progression. The TME is shaped by malignant tumors and evolves over time to evade antitumor immunity. This remains one of the principal obstacles for successful cancer immunotherapy, as discussed in the next section. Challenges in therapeutic targeting of the TME include heterogeneity, such that the nature of the TME may vary in the same tumor in different patients and even at different sites in an individual patient, and the inability to specifically eliminate or block different immunosuppressive components of the TME.

اخر الاخبار

اشترك بقناتنا على التلجرام ليصلك كل ما هو جديد